CAMP
Calamp Corp.

2,497
Loading...
Loading...
News
all
press releases
CAMP4 Analyst Highlights Rare Disease Platform Potential
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036. Latest Ratings for...
Benzinga·10mo ago
News Placeholder
More News
News Placeholder
Why CalAmp (CAMP) Stock Is Down 50%
CalAmp shares are trading lower by 53% during Monday's session. The company announced it will be taken private and initiated Chapter 11 bankruptcy proceedings in Delaware. read more...
Benzinga·1y ago
News Placeholder
Short Interest in CalAmp Corp. (NASDAQ:CAMP) Decreases By 10.3%
CalAmp Corp. (NASDAQ:CAMP - Get Free Report) saw a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 103,200 shares, a drop of 10.3% from the...
Ticker Report·1y ago
News Placeholder
Short Interest in CalAmp Corp. (NASDAQ:CAMP) Decreases By 23.8%
CalAmp Corp. (NASDAQ:CAMP Get Free Report) was the target of a significant decline in short interest in February. As of February 29th, there was short interest totalling 115,100 shares, a...
Ticker Report·2y ago
News Placeholder
CalAmp Corp Extraordinary Shareholders Meeting Transcript
Related Stocks: STU:CF30...
GuruFocus·2y ago
News Placeholder
Q3 2024 CalAmp Corp Earnings Call Transcript
Related Stocks: STU:CF30...
GuruFocus·2y ago
News Placeholder
Q2 2024 CalAmp Corp Earnings Call Transcript
Related Stocks: STU:CF30...
GuruFocus·2y ago
News Placeholder
Q4 2023 CalAmp Corp Earnings Call Transcript
Related Stocks: STU:CF30...
GuruFocus·2y ago
News Placeholder
Q1 2024 CalAmp Corp Earnings Call Transcript
Related Stocks: STU:CF30...
GuruFocus·2y ago
News Placeholder
Q3 2023 CalAmp Corp Earnings Call Transcript
Related Stocks: STU:CF30...
GuruFocus·2y ago

Latest CAMP News

View

Advertisement. Remove ads.

Advertisement. Remove ads.